1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Impact of diabetes on surgery and radiotherapy for breast cancer

      research-article

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purposes

          This study aims to examine whether diabetes has an impact on the use of surgery and adjuvant radiotherapy in treating women with localised breast cancer.

          Methods

          Women diagnosed with stage I–III breast cancer between 2005 and 2020 were identified from Te Rēhita Mate Ūtaetae—Breast Cancer Foundation New Zealand National Register, with diabetes status determined using New Zealand’s Virtual Diabetes Register. The cancer treatments examined included breast conserving surgery (BCS), mastectomy, breast reconstruction after mastectomy, and adjuvant radiotherapy after BCS. Logistic regression modelling was used to estimate the adjusted odds ratio (OR) and 95% confidence interval (95% CI) of having cancer treatment and treatment delay (> 31 days) for patients with diabetes at the time of cancer diagnosis compared to patients without diabetes.

          Results

          We identified 25,557 women diagnosed with stage I–III breast cancer in 2005–2020, including 2906 (11.4%) with diabetes. After adjustment for other factors, there was no significant difference overall in risk of women with diabetes having no surgery (OR 1.12, 95% CI 0.94–1.33), although for patients with stage I disease not having surgery was more likely (OR 1.45, 95% CI 1.05–2.00) in the diabetes group. Patients with diabetes were more likely to have their surgery delayed (adjusted OR of 1.16, 95% CI 1.05–1.27) and less likely to have reconstruction after mastectomy compared to the non-diabetes group—adjusted OR 0.54 (95% CI 0.35–0.84) for stage I cancer, 0.50 (95% CI 0.34–0.75) for stage II and 0.48 (95% CI 0.24–1.00) for stage III cancer.

          Conclusions

          Diabetes is associated with a lower likelihood of receiving surgery and a greater delay to surgery. Women with diabetes are also less likely to have breast reconstruction after mastectomy. These differences need to be taken in to account when considering factors that may impact on the outcomes of women with diabetes especially for Māori, Pacific and Asian women.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

          The 14th St Gallen International Breast Cancer Conference (2015) reviewed new evidence on locoregional and systemic therapies for early breast cancer. This manuscript presents news and progress since the 2013 meeting, provides expert opinion on almost 200 questions posed to Consensus Panel members, and summarizes treatment-oriented classification of subgroups and treatment recommendations.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer.

            In this paper we address methodological aspects of aetiological importance in the link between diabetes and mortality in patients with cancer. We identified nine key points on the cancer pathway at which confounding may arise-cancer screening use, stage at diagnosis, cancer treatment selection, cancer treatment complications and failures, peri-treatment mortality, competing risks for long-term mortality, effects of type 2 diabetes on anti-cancer therapies, effects of glucose-lowering treatments on cancer outcome and differences in tumour biology. Two types of mortality studies were identified: (1) inception cohort studies that evaluate the effect of baseline diabetes on cancer-related mortality in general populations, and (2) cohorts of patients with a cancer diagnosis and pre-existing type 2 diabetes. We demonstrate, with multiple examples from the literature, that pre-existing diabetes affects presentation, cancer treatment, and outcome of several common cancer types, often to varying extents. Diabetes is associated with increased all-cause mortality in cancer patients, but the evidence that it influences cancer-specific mortality is inconsistent. In the absence of data that address the potential biases and confounders outlined in the above framework, we caution against the reporting of cancer-related mortality as a main endpoint in analyses determining the impact of diabetes and glucose-lowering medications on risk of cancer.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer.

              It is unclear how noncancer conditions affect the use or effectiveness of adjuvant therapy among older patients with colon cancer. The authors conducted a cohort study of older patients with stage III colon cancer who were diagnosed from 1993 to 1999 in the Surveillance, Epidemiology, and End Results-Medicare database. The correlations between receipt of adjuvant chemotherapy and heart failure, diabetes, and chronic obstructive pulmonary disease (COPD) were assessed. Multivariable regression analysis was used to assess the risk of death and hospitalization as a function of treatment and comorbidity status. The study sample consisted of 5330 patients (median age, 76 years). The use of adjuvant therapy was related significantly to heart failure (36.2% vs 64.9% of patients with vs without heart failure, respectively; adjusted odds ratio [OR], 0.49; 95% confidence interval [95% CI], 0.40-0.60). More moderate correlations were observed for COPD (OR, 0.83; 95% CI, 0.70-0.99) and diabetes (OR, 0.81; 95% CI, 0.68-0.97). Among patients who had heart failure, the 5-year survival was significantly higher among those who received adjuvant chemotherapy (adjusted 5-year survival rate, 43%; 95% CI, 40-47%) than among those who did not receive adjuvant chemotherapy (30%; 95% CI, 27-34%). Among patients without heart failure, the 5-year survival estimates among treated and untreated patients were 54% (95% CI, 52-56%) and 41% (95% CI, 38-44%), respectively. The probability of all-cause, condition-specific, or toxicity-related hospitalization associated with adjuvant therapy was not altered by the presence of any of the 3 conditions. Although chronic conditions appeared to be a strong barrier to the receipt of adjuvant chemotherapy, adjuvant therapy appeared to provide a significant survival benefit to patients who had colon cancer with the conditions studied. Copyright 2007 American Cancer Society.
                Bookmark

                Author and article information

                Contributors
                Ross.Lawrenson@waikatodhb.health.nz
                chunhuan.lao@waikato.ac.nz
                james.stanley@otago.ac.nz
                Ian.campbell@waikatodhb.health.nz
                jeremy.krebs@otago.ac.nz
                inekemeredith@gmail.com
                Jonathan.Koea@waitematadhb.govt.nz
                andrea.teng@otago.ac.nz
                dianne.sika-paotonu@otago.ac.nz
                jeannine.stairmand@otago.ac.nz
                jason.gurney@otago.ac.nz
                Journal
                Breast Cancer Res Treat
                Breast Cancer Res Treat
                Breast Cancer Research and Treatment
                Springer US (New York )
                0167-6806
                1573-7217
                30 March 2023
                30 March 2023
                2023
                : 199
                : 2
                : 305-314
                Affiliations
                [1 ]GRID grid.49481.30, ISNI 0000 0004 0408 3579, Medical Research Centre, , The University of Waikato, ; Hamilton, New Zealand
                [2 ]GRID grid.413952.8, ISNI 0000 0004 0408 3667, Strategy and Funding, , Waikato Hospital, ; Hamilton, New Zealand
                [3 ]GRID grid.29980.3a, ISNI 0000 0004 1936 7830, Department of Public Health, , University of Otago, ; Wellington, New Zealand
                [4 ]GRID grid.9654.e, ISNI 0000 0004 0372 3343, School of Medicine, , The University of Auckland, ; Auckland, New Zealand
                [5 ]GRID grid.413952.8, ISNI 0000 0004 0408 3667, General Surgery, , Waikato Hospital, ; Hamilton, New Zealand
                [6 ]GRID grid.29980.3a, ISNI 0000 0004 1936 7830, Department of Medicine, , University of Otago, ; Wellington, New Zealand
                [7 ]GRID grid.416918.3, ISNI 0000 0004 0439 7957, General Surgery, , Wakefield Hospital, ; Wellington, New Zealand
                [8 ]General Surgery, Waitakere Hospital, Auckland, New Zealand
                [9 ]GRID grid.9654.e, ISNI 0000 0004 0372 3343, Medical Surgery, , The University of Auckland, ; Auckland, New Zealand
                [10 ]GRID grid.29980.3a, ISNI 0000 0004 1936 7830, Department of Pathology & Molecular Medicine, , University of Otago, ; Wellington, New Zealand
                Author information
                http://orcid.org/0000-0003-0437-8839
                Article
                6915
                10.1007/s10549-023-06915-1
                10175479
                36997750
                c2a11123-8ab0-4d0e-ae37-8b51814ddc1a
                © The Author(s) 2023

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 30 October 2022
                : 13 March 2023
                Funding
                Funded by: New Zealand Health Research Council
                Award ID: 21/068
                Award Recipient :
                Funded by: University of Waikato
                Categories
                Epidemiology
                Custom metadata
                © Springer Science+Business Media, LLC, part of Springer Nature 2023

                Oncology & Radiotherapy
                diabetes,breast cancer,mastectomy,breast conserving surgery,breast reconstruction,treatment delay,radiotherapy

                Comments

                Comment on this article